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Plasma reduced homocysteine concentrations are increased in mmol/L [1, 2]. Mild hyperhomocysteinemia (15 to 30
end-stage renal disease. mmol/L) occurs in subclinical folic acid or vitamin B12
Background. Plasma total homocysteine (tHcy) concentra- deficiency and in most people with chronic renal failuretions .15 mmol/L are associated with an increased risk of
[3–5]. Hyperhomocysteinemia is a strong independentcardiovascular disease. This is especially the case in end-stage
predictor of atherosclerotic vascular events in end-stagerenal disease (ESRD), in which tHcy concentrations commonly
range between 20 and 30 mmol/L. Adverse vascular or pro- renal disease (ESRD) [6–8]. However, the epidemiologic
thrombotic effects associated with hyperhomocysteinemia are evidence relating tHcy and vascular disease does not
assumed to be mediated by the free sulfhydryl (reduced) form establish causality. This requires a plausible pathologicof the molecule (rHcy), but data based on fluorescence high-
mechanism or mechanisms by which homocysteine medi-pressure liquid chromatography (HPLC) indicate that rHcy
ates vascular damage or thrombosis and, ultimately,concentrations are not increased in ESRD despite two- to
threefold elevations in tHcy. demonstration in prospective clinical trials that effective
Methods. We developed a sensitive method for measuring homocysteine-lowering treatments can reduce vascular
plasma rHcy concentrations in which freshly drawn blood is
risk [3, 9]. Such proof is currently lacking.incubated with sodium iodoacetate, and the resulting S-carboxy-
Current hypotheses accounting for homocysteine-methylhomocysteine is analyzed by gas chromatography mass
spectrometry. mediated vascular or thrombotic effects depend on the
Results. Unlike with the earlier methodology, we found reactivity of its free (reduced) sulfhydryl group [1, 3, 9].
plasma rHcy concentrations two to four times higher than Approximately 2% of circulating tHcy is in the reduced
normal in ESRD. These concentrations were lowered by hemo-
form (rHcy), approximately 70% being bound via disul-dialysis and were proportional to plasma tHcy over the range
fide bonds to plasma albumin [10] and another 25 toof tHcy concentrations that has been associated with increased
cardiovascular risk (r 2 5 0.39, P , 0.0001). 30% circulating as free mixed disulfides, mostly homo-
Conclusions. These results support the hypothesis that cysteine-cysteine [11, 12]. The strong predominance of
homocysteine could directly mediate vascular disease through the oxidized forms of homocysteine in plasma is in keep-
mechanisms related to the reactivity of its free sulfhydryl group.
ing with disulfide-sulfhydryl redox potentials, whichIt remains to be determined how much of the variability be-
strongly favor formation of the oxidized partner [13].tween plasma tHcy and rHcy is due to analytical variation and
Thus, while the development of reliable assays for plasmahow much is due to biologic factors that separately influence
concentrations of the disease marker, tHcy, and its presumed tHcy has been an important advance in this field of clini-
mediator, rHcy. cal investigation [1, 14, 15], the tHcy concentrations upon
which current epidemiologic relationships are based are
presumably a surrogate for plasma concentrations of the
The incidence of vascular disease is increased in adults biologically active molecule rHcy [16].
with plasma total homocysteine (tHcy) concentrations As measured by fluorescence high-pressure liquid
only slightly above the normal level of approximately 10 chromatography (HPLC) [17], average normal plasma
rHcy concentrations vary between 0.04 and 0.25 mmol/L
[18–25]. The average rHcy concentration was higher thanKey words: cardiovascular risk factors, chronic renal disease, hemodial-
ysis, hyperhomocysteinemia, plasma total homocysteine. normal in one study of patients with cardiovascular dis-
ease [23], but this was not confirmed in another studyReceived for publication February 10, 2000
despite increased tHcy concentrations in the patientsand in revised form July 31, 2000
Accepted for publication August 4, 2000 with disease [26]. Moreover, plasma rHcy was found to
be normal in ESRD despite twofold to threefold in-Ó 2001 by the International Society of Nephrology
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creases in tHcy [17, 22]. This has led to the conclusion subjects. Each blood sample was immediately separated
into three collection tubes: one for routine serum clinicalthat apart from certain non–steady-state conditions
[20, 27], plasma rHcy remains constant as plasma tHcy chemistry, a second for the tHcy measurement by HPLC
(described later in this article), and the third for rHcy.increases, only rising importantly after albumin’s homo-
cysteine-binding capacity is exceeded at tHcy concentra- The rHcy derivatization procedure was similar to that
used by Brigham, Stein, and Moore [30] and subse-tions .100 mmol/L [17]. If correct, this challenges current
understanding of the mechanisms by which homocys- quently by Chawla et al [31] to measure reduced cysteine
with an amino acid analyzer. Within a minute of collec-teine could mediate vascular pathology. It is possible
that plasma rHcy is rapidly taken up into cells or con- tion, a 6 mL aliquot of whole blood was added to a
collection tube containing 12 mg potassium ethylenedi-verted into another reactive form in the circulation, but
even if this is so, it is hard to understand how the mildly aminetetraacetic acid (EDTA; Vacutainer, Becton Dick-
inson, Franklin Lakes, NJ, USA) and 0.7 mL of a solutionincreased tHcy concentrations associated with vascular
disease could translate into greater rHcy mass effect containing 0.48 mol/L sodium iodoacetate. This solution
was prepared the morning of the study and consisted ofor metabolic transformation [28] without a concurrent
measurable increase in plasma rHcy. 1.0 g of sodium iodoacetate (Sigma Chemical Co., St.
Louis, MO, USA) and 0.42 g sodium bicarbonate in 10In an attempt to explore this paradox, we measured
plasma rHcy by fluorescence HPLC [19], but found the mL of 0.1 mol/L aqueous sodium phosphate buffer, pH
6.8. After addition of the blood sample to the collectionmethod insufficiently sensitive for accurate use in our
laboratory. This stimulated us to develop a gas chroma- tube, the contents were immediately mixed by several
gentle inversions, and the tube was kept in crushed icetography mass spectrometry (GCMS) method with ade-
quate sensitivity to detect rHcy concentrations of normal for at least 20 minutes to allow formation of the S-carboxy-
methyl derivative of Hcy. Plasma was obtained by cen-persons and those with ESRD. Our results using this
method indicate that plasma rHcy concentrations are trifugation at 48C for 10 minutes and was stored at 2308C
for as long as several months without removing the iodo-indeed increased in ESRD, and they are directly propor-
tional to tHcy concentrations over the range of tHcy con- acetate. At the time of analysis, 0.6 nmol of the internal
standard DL-[3,3,4,4-2H4]S-carboxymethylhomocysteinecentrations associated with increased cardiovascular risk.
was added to 0.8 mL of freshly thawed plasma, and the
mixture was purified by acidification with 1.5 mL 1.0 mol/L
METHODS
acetic acid and passage into a 1 mL bed of strong cation-
Research subjects exchange resin (Dowex 50 W-X8, 100-200 mesh, hydro-
gen form; Bio-Rad Laboratories, Hercules, CA, USA),These were 13 normal adults (age 36 6 4 years, weight
63.5 6 3.4 kg; all values mean 6 SEM) and 50 ESRD followed by a 4 mL water wash, and finally, elution of the
S-carboxymethylhomocysteine with three 1 mL additionspatients receiving maintenance renal replacement ther-
apy in two Montreal hemodialysis units; their tHcy con- of 3 mol/L ammonium hydroxide. The eluate was dried
gently under a stream of nitrogen at 608C, dissolved incentrations have previously been reported [29]. Plasma
rHcy was measured before and after dialysis in 25 of the 75 mL of acetonitrile at 608C for one hour, and then in-
cubated with 75 mL N-methyl-N-(tert-butyldimethylsilyl)-26 study participants in the first unit and prior to dialysis
in a random set of 25 of the 67 participants in the second trifluoroacetamide (Regis Technologies, Inc., Morton
Grove, IL, USA) at the same temperature for 30 minutesunit. The patients in the two units were clinically stable
with plasma albumin concentrations over 35 g/L and to form tert-butyldimethylsilyl (TBDMS) derivatives.
Plasma from blood collected in EDTA was analyzedsimilar serum urea and creatinine concentrations (age
68 6 2 years, predialysis weight 68.9 6 2.4 kg, serum for tHcy in the conventional manner by HPLC following
reduction of all disulfides using tri-N-butylphosphineurea 25 6 1 mmol/L, serum creatinine 704 6 35 mmol/L,
serum albumin 40 6 1 g/L). The average plasma tHcy (TBP; Sigma), and conversion to a fluorescent derivative
with 7-fluorobenzofurazane-4-sulfonic acid (Sigma), as pre-was significantly lower in the second hemodialysis unit,
caused perhaps by the high-dose vitamin B12 therapy viously described [29]. To test the new GCMS method, we
modified it to measure tHcy and compared the resultsused there [29]; this provided a conveniently wide range
of tHcy concentrations over which to compare the rHcy with those from the established HPLC method. For this
procedure, 20 mL of the reducing agent tris-(2-carboxy-concentrations reported in this article. This research was
approved by the institutional review boards of the two ethyl)phosphine hydrochloride (TCEP-HCl; Pierce Chem-
ical Co., Rockford, IL, USA; 10% in water) were addedhospitals and McGill University.
to 200 mL of plasma [32], and reduction was allowed to
Sample treatment proceed at room temperature for 30 minutes, after which
0.2 mL of ice-cold 0.6 mol/L trichloroacetic acid inBlood was drawn from the normal subjects by veni-
puncture and from the arteriovenous fistula of the ESRD 1 mmol/L EDTA was added to precipitate plasma pro-
Hoffer et al: Reduced homocysteine in ESRD374
teins. (Both TCEP-HCl and TBP were very effective and internal standards added to plasma. To overcome
this problem, calibration standards were prepared fromreducing agents, as was verified in preliminary experi-
ments using large amounts of unlabeled homocystine, a stock of pooled stored plasma. Endogenous rHcy de-
tected in the stored plasma was corrected for by sub-with the product rHcy measured by HPLC.) A 100 mL
aliquot of the resulting supernatant was mixed with 100 tracting the nonzero intercept corresponding to the blank
standard from the calibration curve.mL of 0.1 mol/L potassium tetraborate in 4 mmol/L
EDTA (pH 10.5), and after near-neutral pH was verified,
Instrumentation and analysis20 mL of 0.48 mol/L sodium iodoacetate solution were
added, and the mixture was allowed to react for 20 min- The gas chromatograph (GC) was an HP 5890 (Hew-
lett-Packard, Palo Alto, CA, USA) directly coupled to anutes at room temperature. The sample was then prepared
for GCMS analysis as described earlier. HP 5988A quadruple mass spectrometer (MS). Samples
(3.0 mL) were introduced by splitless injection using an
Preparation of standards and internal standards HP 7673 autoinjector onto a fused silica DB-1 capillary
column (30 m 3 0.25 mm, 0.25 mm film thickness; J & WS-carboxymethylcysteine and S-carboxymethylhomo-
cysteine were synthesized by treating l-cysteine or DL- Scientific, Folsom, CA, USA). The initial temperature
was 1808C, held for one minute, and it was brought toHcy (both from Sigma) with an amount of sodium io-
doacetate solution that provided a large molar excess of a final column temperature of 2768C at a rate of 88C per
minute. Helium carrier gas was used at a column headiodoacetate/sulfhydryl. Stock solutions (10 mmol/L) of
the resulting carboxymethylated derivatives were stored pressure of 70 kPa. Injector port and transfer line tem-
peratures were 2508C. Electron-impact MS was used withat 2308C without removing the iodoacetate and were
found to be stable for at least one year. Working solu- ionizing energy of 70 eV, emission current of 300 mA,
and a source temperature of 2008C. Quantitation wastions were 100 mmol/L. As S-carboxymethylcysteine is
commercially available (Sigma), we tested the efficiency performed by selected ion monitoring of the [M-C4H9]1
of cysteine carboxymethylation against this standard and fragment ions of the TBDMS derivatives with the follow-
found it to be approximately 100%. ing mass to charge (m/z) ratios: S-carboxymethylhomo-
Synthesis of the S-carboxymethylhomocysteine inter- cysteine (M0), 478.3 [2H4]S-carboxymethylhomocysteine
nal standard required prior reduction of DL-[3,3,39,39, (M 1 4), 482.3. The usual retention time was 13.9 min-
4,4,49,49-2H8]homocystine (CDN Isotopes, Pointe-Claire, utes. Data acquisition and processing were done on an
Quebec, Canada) to [2H4]rHcy. To carry out this reaction HP-1000A computer using RTE-A primary system soft-
0.5 mL of a 5 mmol/L solution of [2H8]homocystine in ware. The (478.3)/(482.3) signal intensity ratio was inter-
0.05 mol/L sulfosalicylic acid and 0.3 mL of 10% (wt/wt) preted using an areas ratio calibration curve developed
TBP in N,N-dimethyl formamide (Regis Technologies, using standards prepared in stored plasma and included
Inc.), or alternatively, 0.3 mL of 10% TCEP-HCl in water in each analytical run. The resulting rHcy concentrations
was added to 4.2 mL of 0.1 mol/L sodium phosphate were accurately corrected for approximately 10% sample
buffer. The reduction proceeded at room temperature dilution introduced by the sodium iodoacetate solution
for one hour (TBP) or 30 minutes (TCEP-HCl). A 5 by weighing the collection tubes before and after addi-
mL volume of iodoacetate solution (0.047 g of sodium tion of the original blood sample.
iodoacetate, 0.01 g EDTA, and 0.021 g sodium bicarbon-
ate in 5 mL of 0.1 mol/L sodium phosphate buffer) was
RESULTSthen added, and the mixture was allowed to react at
Typical selected ion monitoring chromatograms illus-room temperature for 20 minutes. The volume was then
trating peak relative intensities at masses 478 and 482made up to 50 mL with the same sodium phosphate
are shown in Figure 1. The recovery of DL-homocysteinebuffer, yielding an approximately 100 mmol/L solution
added to fresh whole blood in amounts comparable toof [2H4]S-carboxymethylhomocysteine. The concentra-
the normal endogenous concentration was 98 6 3%. Rep-tion of this deuterium-labeled internal standard was pre-
licate within-sample results usually differed by ,10%.cisely measured by GCMS using unlabeled S-carboxy-
Figure 2 illustrates the good agreement between tHcymethylhomocysteine as the internal standard.
concentrations measured by HPLC fluorescence and
Calibration curve with the new GCMS method in a sample of patients and
control subjects.Excellent electron-impact GCMS signals were ob-
The average plasma tHcy and rHcy concentrations oftained for plasma samples and large amounts of pure
the 13 normal adults were 8.47 6 0.58 and 0.24 6 0.03rHcy, but when small amounts of standard or internal
mmol/L, respectively; both are within the range of normalstandard comparable to those in plasma were analyzed
values reported using earlier methods. The predialysisin water, the signal was approximately 20-fold less in-
tense than from rHcy endogenous to plasma or standards tHcy concentration of the ESRD patients was 21.5 6
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Fig. 1. Typical [M-C4H9]1 selected ion chro-
matograms for the tri-t-butyldimethylsilyl de-
rivatives of S-carboxymethylhomocysteine (m/z
478, A) and internal standard [2H4]S-carboxy-
methylhomocysteine (m/z 482, B) extracted
from sodium iodoacetate-treated plasma of a
normal subject.
Fig. 3. Regression analysis for plasma total versus reduced homocys-
Fig. 2. Regression analysis for plasma total homocysteine (tHcy) as teine in 63 persons. Symbols are: (d) data for the 13 normal persons;
measured by high-pressure liquid chromatography (HPLC) fluores- (s) data for the 50 patients with ESRD prior to hemodialysis [r 2 5
cence vs. gas chromatography-mass spectrometry (GCMS) in 12 sub- 0.394, P , 0.0001; y 5 (0.15 6 0.08) 1 (0.025 6 0.004)x].
jects with varying tHcy concentrations [r 2 5 0.965, P , 0.0001; y 5
(21.32 6 1.50) 1 (1.13 6 0.07)x].
DISCUSSION
Our results are important because they indicate—in
1.1 mmol/L, a value 2.5 times higher than normal (P , contrast to previous studies using a less sensitive method—
0.0001). Their rHcy was 0.72 6 0.04 mmol/L, three times that steady-state plasma rHcy concentrations are in-
higher than normal (P , 0.0001). Plasma rHcy and tHcy creased in ESRD and vary directly with tHcy over the
concentrations were strongly related for tHcy concentra- range of tHcy concentrations that has been associated
tions ranging from normal to high (Fig. 3). Dialysis sig- with increased vascular risk. Previous studies indicated
nificantly lowered both t-and rHcy concentrations, as that plasma rHcy concentrations remain constant as tHcy
[17, 22] and free mixed homocysteine-disulfide [33] con-shown in Figure 4.
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methylhomocysteine formed upon exposure of a freshly
drawn sample of whole blood to sodium iodoacetate
without prior sample reduction.
The GCMS method described here for rHcy is more
complex than the widely available and reliable fluores-
cence HPLC method for measuring tHcy. Moreover, it
requires rapid sample processing and, hence, would not
be useful for clinical screening. The prime importance
of our report is its demonstration of a plausible link
between the clinical marker of disease risk, plasma tHcy,
and its presumed mediator, rHcy. However, one should
not neglect the possibility that a sensitive technique for
measuring rHcy could be very useful in clinical research
[16]. McCully, who first predicted that mild hyperhomo-
cysteinemia could mediate vascular disease, has pointed
out the narrow difference and considerable overlap be-
tween the tHcy levels of affected and control groups
[36]. The relationship between plasma rHcy and tHcy
observed in the present study was strong, but still ac-
counted for only 40% of the variance between them. It
remains to be determined how much of the residual
Fig. 4. Effect of hemodialysis on plasma total and reduced homocys- variance is due to analytical variation and how much is
teine concentrations in 25 patients with end-stage renal disease (ESRD).
due to biologic factors separately influencing the plasmaPrior to dialysis (s), tHcy was 23.7 6 1.4 mmol/L and rHcy was 0.84 6
0.07 mmol/L. After dialysis (d), tHcy was 14.5 6 0.8 mmol/L and rHcy concentrations of the risk marker, tHcy, and the pre-
was 0.29 6 0.02 mmol/L (P , 0.0001). sumed disease mediator, rHcy.
NOTE ADDED IN PROOF
centrations increase, implying that the homocysteine-
Since completion of this study the assay has been im-
disulfide/rHcy redox potential changes as tHcy concen- proved by mixing the blood sample with 0.12 mL rather
trations change [17]. Since current theories implicating than 0.7 mL of the derivatizing solution, and purifying by
a biologic role for homocysteine in vascular disease are cation exchange chromatography immediately following
based on the chemical reactivity of its free sulfhydryl formation of the S-carboxymethylhomocysteine deriva-
group, it is difficult to understand how increased plasma tive.
tHcy could mediate vascular disease without a corre-
sponding increase in rHcy. The present observations in- ACKNOWLEDGMENTS
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